The current financial score of bioAffinity Technologies Inc is 6.10. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.51M, representing a year-over-year increase of 18.99%, while its net profit experienced a year-over-year increase of 17.11%.
The current valuation score of bioAffinity Technologies Inc is 8.99. Its current P/E ratio is -2.07, which is -98.25% below the recent high of -0.04 and -267.14% above the recent low of -7.59.
No earnings forecast score is currently available for bioAffinity Technologies Inc. The Healthcare Equipment & Supplies industry's average is 7.76.
The current price momentum score of bioAffinity Technologies Inc is 8.87. Currently, the stock price is trading between the resistance level at 18.33 and the support level at 2.54, making it suitable for range-bound swing trading.
The current institutional shareholding score of bioAffinity Technologies Inc is 3.00. The latest institutional shareholding proportion is 6.48%, representing a quarter-over-quarter increase of 1580.36%.
The current risk assessment score of bioAffinity Technologies Inc is 1.29. The company's beta value is -1.31. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.